Literature DB >> 14664763

The role of positron emission tomographic imaging in breast cancer.

Michelle D McDonough1, Elizabeth R DePeri, Betty A Mincey.   

Abstract

Studies have shown that deoxy-2-fluorodeoxyglucose ((18)FDG) positron emission tomography (PET) has limited value in detecting primary tumors and axillary lymph node involvement in breast cancer. PET is most successful when it is used to evaluate locally advanced breast tumors. Identification of smaller, earlier-stage tumors and noninvasive or lobular tumors has been suboptimal. Because of several factors, PET should not replace standard techniques for evaluation of breast cancer, especially for micrometastasis. However, PET can provide invaluable information about disease extent, recurrent disease, and distant metastases, and this information can affect treatment decisions. (18)FDG PET can also facilitate the differentiation of therapy responders from nonresponders, allowing treatment regimen changes at an earlier stage.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14664763     DOI： 10.1007/s11912-996-0011-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  39 in total

1.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.

Authors:  R L Wahl; R L Cody; G D Hutchins; E E Mudgett
Journal:  Radiology       Date:  1991-06       Impact factor: 11.105

2.  The Potential of F-18-FDG PET in Breast Cancer. Detection of Primary Lesions, Axillary Lymph Node Metastases, or Distant Metastases.

Authors:  K F. Hubner; G T. Smith; J A. Thie; J L. Bell; H S. Nelson; W T. Hanna
Journal:  Clin Positron Imaging       Date:  2000-09

3.  Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.

Authors:  N Avril; C A Rosé; M Schelling; J Dose; W Kuhn; S Bense; W Weber; S Ziegler; H Graeff; M Schwaiger
Journal:  J Clin Oncol       Date:  2000-10-15       Impact factor: 44.544

4.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.

Authors:  I C Smith; A E Welch; A W Hutcheon; I D Miller; S Payne; F Chilcott; S Waikar; T Whitaker; A K Ah-See; O Eremin; S D Heys; F J Gilbert; P F Sharp
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

5.  Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

Authors:  I C Smith; K N Ogston; P Whitford; F W Smith; P Sharp; M Norton; I D Miller; A K Ah-See; S D Heys; J A Jibril; O Eremin
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

6.  Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?

Authors:  T Jansson; J E Westlin; H Ahlström; A Lilja; B Långström; J Bergh
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

7.  Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.

Authors:  R L Wahl; K Zasadny; M Helvie; G D Hutchins; B Weber; R Cody
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

8.  Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: review of 183,134 screening mammograms in Albuquerque, New Mexico.

Authors:  R D Rosenberg; W C Hunt; M R Williamson; F D Gilliland; P W Wiest; C A Kelsey; C R Key; M N Linver
Journal:  Radiology       Date:  1998-11       Impact factor: 11.105

9.  Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer.

Authors:  O E Nieweg; E E Kim; W H Wong; W F Broussard; S E Singletary; G N Hortobagyi; R S Tilbury
Journal:  Cancer       Date:  1993-06-15       Impact factor: 6.860

10.  Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.

Authors:  F Dehdashti; J E Mortimer; B A Siegel; L K Griffeth; T J Bonasera; M J Fusselman; D D Detert; P D Cutler; J A Katzenellenbogen; M J Welch
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057
View more
  4 in total

Review 1.  Prevalence and clinical significance of incidental F18-FDG breast uptake: a systematic review and meta-analysis.

Authors:  Francesco Bertagna; Giorgio Treglia; Emanuela Orlando; Lodovica Dognini; Luca Giovanella; Ramin Sadeghi; Raffaele Giubbini
Journal:  Jpn J Radiol       Date:  2013-12-13       Impact factor: 2.374

2.  Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients.

Authors:  Barbara J Fueger; Wolfgang A Weber; Andrew Quon; Tyler L Crawford; M S Allen-Auerbach; B S Halpern; Osman Ratib; Michael E Phelps; Johannes Czernin
Journal:  Mol Imaging Biol       Date:  2005 Sep-Oct       Impact factor: 3.488

Review 3.  The choice of the correct imaging modality in breast cancer management.

Authors:  Emilio Bombardieri; Luca Gianni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-04       Impact factor: 9.236

4.  Clinical Value of Three Combined Ultrasonography Modalities in Predicting the Risk of Metastasis to Axillary Lymph Nodes in Breast Invasive Ductal Carcinoma.

Authors:  Qing Zhang; Enock Adjei Agyekum; Linna Zhu; Lingling Yan; Lei Zhang; Xian Wang; Liang Yin; Xiaoqin Qian
Journal:  Front Oncol       Date:  2021-09-22       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.